ezer21 LLC

About ezer21 LLC

Most early-stage medtech companies are investment ready. They have the deck, the team, and enough data to get in the room. Far fewer are investment grade, where the risks are mapped, capital deployment is traceable, and the story arrives before the question. Ezer21 closes that gap. We build and run the operating system that connects cash, risk, and narrative into a single instrument for value creation, so every dollar a company spends retires a risk investors actually price. Every engagement starts with the Underwrite Score, a thirty day structural diagnostic that grades a company across six dimensions and hands the CEO a playbook for what to fix first. We work with CEOs of Class I to III medical technology companies, pre-clearance through early revenue, as a CFO embedded in the business rather than a vendor delivering reports. A second strategic authority in the room, the partner who connects cash to risk to story and holds the longest time horizon in every conversation. From investment ready to investment grade.